With 0.6 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.17 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $97.99 whereas the lowest price it dropped to was $85.03. The 52-week range on PVLA shows that it touched its highest point at $87.01 and its lowest point at $11.17 during that stretch. It currently has a 1-year price target of $128.83. Beta for the stock currently stands at -0.17.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of PVLA was up-trending over the past week, with a rise of 18.85%, but this was up by 28.09% over a month. Three-month performance surged to 88.87% while six-month performance rose 321.35%. The stock gained 707.58% in the past year, while it has gained 510.73% so far this year. A look at the trailing 12-month EPS for PVLA yields -12.61 with Next year EPS estimates of -3.92. For the next quarter, that number is -0.90. This implies an EPS growth rate of 55.24% for this year and -11.93% for next year. EPS is expected to grow by 9.80% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 29.42%.
Float and Shares Shorts:
At present, 13.77 million PVLA shares are outstanding with a float of 7.43 million shares on hand for trading. On 2025-10-31, short shares totaled 0.75 million, which was 680.0000000000001 higher than short shares on 1759190400. In addition to Mr. Wesley H. Kaupinen as the firm’s Founder, President, CEO & Director, Ms. Kathleen Goin serves as its Chief Operating Officer.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-09-30, PVLA reported revenue of $0.0 and operating income of -$10177000.0. The EBITDA in the recently reported quarter was -$9515000.0 and diluted EPS was -$1.03.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With PVLA analysts setting a high price target of 200.0 and a low target of 87.0, the average target price over the next 12 months is 124.58333. Based on these targets, PVLA could surge 106.38% to reach the target high and fall by -10.23% to reach the target low. Reaching the average price target will result in a growth of 28.56% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$2.31965 being high and -$3.35657 being low. For PVLA, this leads to a yearly average estimate of -$2.84195. The surprise factor in the prior quarter was -$0.77. Based on analyst estimates, the high estimate for the next quarter is -$0.81 and the low estimate is -$0.98. The average estimate for the next quarter is thus -$0.87.
